

## CLAIMS

1. Triiodothyronine sulfate for use as a medicament.
2. Triiodothyronine sulphate for use as a medicament according to 5 claim 1, having thyromimetic activity.
3. Triiodothyronine sulfate according to claim 2, for use in the treatment of pathologies due to organic deficiency of triiodothyronine.
4. Triiodothyronine sulfate according to claim 3, wherein said pathologies comprise original hypothyroidism from autoimmune thyroid 10 affections, hormonal production defects, thyroidectomy, congenital hypothyroidism.
5. Triiodothyronine sulfate according to claim 2, for use in the treatment of disorders due to reduced activity of type I 5'-iodothyronine monodeiodinase.
- 15 6. Triiodothyronine sulfate according to claim 5, wherein said reduced activity of type I 5'-iodothyronine monodeiodinase comprises, among its grounds, hypothyroidism, non thyroidal systemic illnesses, fast, selenium shortage.
7. Pharmaceutical compositions comprising triiodothyronine sulfate as 20 an active principle.
8. Pharmaceutical compositions according to claim 7, wherein said triiodothyronine sulfate is formulated in association with thyroxine.
9. Pharmaceutical compositions according to claim 7 and 8, wherein 25 said compositions further comprise additives like excipients, diluents, dissolvents, solvents, carriers, dyestuffs, flavourings, sweeteners.
10. Pharmaceutical compositions according to claim 7, wherein triiodothyronine sulfate is administered at doses ranging from 5 to 1000 µg.

11. Pharmaceutical compositions according to claim 10, wherein triiodothyronine sulfate is administered at doses ranging from 10 to 500  $\mu$ g.
12. Pharmaceutical compositions according to claim 10, wherein triiodothyronine sulfate is administered at doses ranging from 25 to 250  $\mu$ g.
- 5 13. Pharmaceutical compositions according to claim 8, wherein said association is administered at doses ranging from 10 to 500  $\mu$ g of triiodothyronine sulfate and from 10 to 250  $\mu$ g of thyroxine.
- 10 14. Pharmaceutical compositions according to claim 8, wherein said association is administered at doses ranging from 25 to 250  $\mu$ g of triiodothyronine sulfate and from 25 to 200  $\mu$ g of thyroxine.
15. Kit for the differential or sequential administration of the pharmaceutical compositions according to claims 8, 9 and 11 to 14.
16. Use of triiodothyronine sulfate for the preparation of the pharmaceutical compositions according to claims 7 to 15.